# Supernus Pharmaceuticals, Inc.: overview

SUPN · Nasdaq · CIK 1356576 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/supn.md) · [Financials](/companies/supn/financials.md) · [Filings](/companies/supn/filings.md) · [Insiders](/companies/supn/insiders.md)

Latest reported revenue: [$226.8m](/filings/0001356576-26-000051.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001356576-26-000051).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [174 d](/filings/0001356576-26-000011.md) | [150](/filings/0001356576-26-000022.md) | [165](/filings/0001356576-26-000037.md) | [192](/filings/0001356576-26-000051.md) | [212 d](/filings/0001356576-26-000011.md) | [208](/filings/0001356576-26-000022.md) | [219](/filings/0001356576-26-000037.md) | [227](/filings/0001356576-26-000051.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [12.3% d](/filings/0001356576-26-000011.md) | [(6.8%)](/filings/0001356576-26-000022.md) | [7.3%](/filings/0001356576-26-000037.md) | [(31.4%)](/filings/0001356576-26-000051.md) | [(1.9%) d](/filings/0001356576-26-000011.md) | [(4.0%)](/filings/0001356576-26-000022.md) | [(26.5%)](/filings/0001356576-26-000037.md) | [9.3%](/filings/0001356576-26-000051.md) |
| Net margin | % | [8.8% d](/filings/0001356576-26-000011.md) | [(7.9%)](/filings/0001356576-26-000051.md) | [13.6%](/filings/0001356576-26-000051.md) | [(23.5%)](/filings/0001356576-26-000051.md) | [(1.9%) d](/filings/0001356576-26-000011.md) | [(1.1%)](/filings/0001356576-26-000051.md) | [(26.6%)](/filings/0001356576-26-000051.md) | [9.2%](/filings/0001356576-26-000051.md) |
| Diluted EPS | $ per share | not reported | [(0.21)](/filings/0001356576-26-000022.md) | [0.40](/filings/0001356576-26-000037.md) | [(0.80)](/filings/0001356576-26-000051.md) | not reported | [(0.04)](/filings/0001356576-26-000022.md) | [(1.01)](/filings/0001356576-26-000037.md) | [0.35](/filings/0001356576-26-000051.md) |
| Free cash flow | $m | [44.2 d](/filings/0001356576-26-000011.md) | [30.3](/filings/0001356576-26-000022.md) | [58.1 d](/filings/0001356576-26-000037.md) | [(61.8) d](/filings/0001356576-26-000051.md) | [19.4 d](/filings/0001356576-26-000011.md) | [66.5](/filings/0001356576-26-000022.md) | [(5.4) d](/filings/0001356576-26-000037.md) | [6.4 d](/filings/0001356576-26-000051.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [580](/filings/0001356576-23-000016.md) | [667](/filings/0001356576-25-000017.md) | [608](/filings/0001356576-26-000011.md) | [662](/filings/0001356576-26-000011.md) | [719](/filings/0001356576-26-000011.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [14.8%](/filings/0001356576-23-000016.md) | [6.9%](/filings/0001356576-25-000017.md) | [(0.9%)](/filings/0001356576-26-000011.md) | [12.3%](/filings/0001356576-26-000011.md) | [(8.7%)](/filings/0001356576-26-000011.md) |
| Net margin | % | [9.2%](/filings/0001356576-23-000016.md) | [9.1%](/filings/0001356576-25-000017.md) | [0.2%](/filings/0001356576-26-000011.md) | [11.2%](/filings/0001356576-26-000011.md) | [(5.4%)](/filings/0001356576-26-000011.md) |
| Diluted EPS | $ per share | [0.98](/filings/0001356576-23-000016.md) | [1.04](/filings/0001356576-25-000017.md) | [0.02](/filings/0001356576-26-000011.md) | [1.32](/filings/0001356576-26-000011.md) | [(0.68)](/filings/0001356576-26-000011.md) |
| Free cash flow | $m | not reported | [116](/filings/0001356576-25-000017.md) | [111](/filings/0001356576-26-000011.md) | [171](/filings/0001356576-26-000011.md) | [46.0](/filings/0001356576-26-000011.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/supn/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $434.9m | 9,350,046 |  | Added +552,792 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $179.2m | 3,853,212 |  | Added +537,239 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $153.7m | 3,305,429 |  | Added +66,736 |
| [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $123.1m | 2,646,201 |  | Added +750,854 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $117.1m | 2,516,721 |  | Added +49,506 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $114.4m | 2,459,828 |  | Added +171,701 |
| [NOMURA ASSET MANAGEMENT INTERNATIONAL INC.](/funds/921739.md) | 2026-06-30 | $110.6m | 2,378,329 |  | Added +341,127 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $96.7m | 2,078,090 |  | Reduced −228,940 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $73.0m | 1,570,088 |  | Reduced −53,426 |
| [Stephens Investment Management Group LLC](/funds/1314440.md) | 2026-06-30 | $69.1m | 1,485,821 |  | Added +134,490 |

## Recent filings

[All 1,184 filings](/companies/supn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:12 ET | [10-Q](/filings/0001356576-26-000051.md) | Quarterly report, period 2026-09-30 | 0001356576-26-000051 |
| 2026-10-29 | 16:08 ET | [8-K](/filings/0001356576-26-000050.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001356576-26-000050 |
| 2026-10-26 | 16:41 ET | [8-K](/filings/0001356576-26-000045.md) | 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001356576-26-000045 |
| 2026-10-22 | 21:07 ET | [8-K](/filings/0001104659-26-117937.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-117937 |
| 2026-10-19 | 16:51 ET | [8-K](/filings/0001356576-26-000043.md) | 2.02 Results of operations | 0001356576-26-000043 |
| 2026-10-15 | 16:10 ET | [8-K](/filings/0001356576-26-000040.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001356576-26-000040 |
| 2026-08-03 | 17:00 ET | [8-K](/filings/0001104659-26-089839.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-089839 |
| 2026-08-03 | 08:34 ET | [8-K](/filings/0001104659-26-089524.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-089524 |
| 2026-08-03 | 06:56 ET | [10-Q](/filings/0001356576-26-000037.md) | Quarterly report, period 2026-06-30 | 0001356576-26-000037 |
| 2026-08-03 | 06:46 ET | [8-K](/filings/0001356576-26-000035.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001356576-26-000035 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001356576-26-000011.md), filed Mar 2, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1356576
- Tickers: SUPN
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:38 ET. No prices; not investment advice.